Histone deacetylation in epigenetics: An attractive target for anticancer therapy

Medicinal Research Reviews

Volumn 25, Issue 3, 2005, Pages 261-309

  Mai, Antonello ^a   Massa, Silvio ^b   Rotili, Dante ^a   Cerbara, Ilaria ^a   Valente, Sergio ^a   Pezzi, Riccardo ^a   Simeoni, Silvia ^a   Ragna, Rino ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Anticancer chemotherapy; Class selectivity; Clinical trials; Epigenetics; HDAC inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; APICIDIN; CYCLO[LEUCYLPIPECOLYL (2 AMINO 8 OXO 9,10 EPOXYDECANOYL) DEXTRO PHENYLALANYL]; DEPUDECIN; FR 901228; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; OXAMFLATIN; REELIN; TRAPOXIN; TRAPOXIN A; TRAPOXIN B; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN STRUCTURE; DEACETYLATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; IN VIVO STUDY; REVIEW; TRANSCRIPTION REGULATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DRUG DESIGN; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; MODELS, MOLECULAR; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 16844362441     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20024     Document Type: Review

References (241)

1. Lengauer C, Issa JP. The role of epigenetics in cancer: DNA methylation, imprinting, and the epigenetics of cancer. Mol Med Today 1998;4:102-103.
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
3. Mukesh V, Sudhir S. Epigenetics in cancer: Implications for early detection and prevention. Lancet Oncol 2002;3:755-763.
4. Fire A. Potent and specific genetic interference by double-stranded RNA in Caenorhabdltis elegans. Nature 1998;391:806-811.
5. Baylin SB. Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science 1997;277: 1948-1949.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: 415-428.
7. Takacs M, Salamon D, Myohanen S. Epigenetics of latent Epstein-Barr virus genomes: High resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes. Biol Chem 2001;382:699-705.
8. Tierney RJ, Kirby HE, Nagra JK. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J Virol 2000;74:10468-10479.
9. Robertson KD. The role of DNA methylation in modulating Epstein-Barr virus gene expression. Curr Top Microbiol Immunol 2000;249:21-34.
10. Tao Q, Swinnen LJ, Yang J. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease: Application of PCR-based analysis. Am J Pathol 1999;155:619-625.
11. Hagan CR, Rudin CM. Mobile genetic element activation and genotoxic cancer therapy: Potential clinical implications. Am J Pharmacogenomics 2002;2:25-35.
12. Nelson WG, De Marzo AM, De Weese TL. Preneoplastic prostate lesions: An opportunity for prostate cancer prevention. Ann NY Acad Sci 2001;952:135-144.
13. Rideout WM, Eggan K, Jaenisch R. Nuclear cloning and epigenetic reprogramming of the genome. Science 2001;293:1093-1098.
14. Nelson WG, De Marzo AM, De Weese TL. The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. Urology 2001;57:39-45.
15. Howell CY, Bestor TH, Ding F. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt 1 gene. Cell 2001;104:829-838.
16. El-Osta A, Wolffe AP. DNA methylation and histone deacetylation in the control of gene expression: Basic biochemistry to human development and disease. Gene Exp 2000;9:63-75.
17. Zuccotti M, Garagna S, Redi CA. Nuclear transfer, genome reprogramming, and novel opportunities in cell therapy. J Endocrinol Invest 2000;23:623-629.
18. Avner P, Heard E. X-chromosome inactivation: Counting, choice, and initiation. Nat Rev Genet 2001; 2:59-67.
19. Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 2001;98:392-394.
20. Dennis C. Altered states. Nature 2003;421:686-688.
21. Maier S, Olek A. Diabetes: A candidate disease for efficient DNA methylation profiling. J Nutr Sci 2002;132:2440-2443.
22. Lumey LH. Decreased birth weights in infants after maternal in utero exposure to the dutch famine of 1944-1945. Paediatr Perinat Epidemiol 1992;6:240-253.
23. Kaati G, Bygren LO, Edvisson S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur J Hum Genet 2002;10:682-688.
24. Morgan HD, Sutherland HGE, Martin DIK, Whitelaw E. Epigenetic inheritance at the agouti locus in the mouse. Nat Genet 1999;23:314-318.
25. Sollars V. Evidence for an epigenetic mechanism by which Hsp90 act as a capacitor for morphological evolution. Nat Genet 2003;33:70-74.
26. Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltransferases of mouse cell. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 1988;203:971-983.
27. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998;19:219-220.
28. Larsen F, Gundersen G, Lopez R, Prydz H. CpG islands as gene markers in the human genome. Genomics 1992;13:1095-1107.
29. Jones PL. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-191.
30. Nan X. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
31. Constancia M, Dean W, Lopes S, Moore T, Kelsey G, Reik W. Deletion of a silencer element in IgA2 results in loss of imprinting independent H19. Nat Genet 2000;26:203-206.
32. Eden S. An upstream repressor element plays a role in IgA2 imprinting. EMBO J 2001;20:3518-3525.
33. Hark AT. CTCF mediated methylation-sensitive enhancer-blocking activity at the H19/IgA2 locus. Nature 2000;405:486-489.
34. Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet 1988;78:151-155.
35. Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcitosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990;249:1288-1290.
36. Esteller M, Catasus L, Matias-Guiu X. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999;155:1767-1772.
37. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
38. Esteller M, Sanchez-Cespedes M, Rosell R. Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
39. Tycko B. Epigenetic gene silencing in cancer. J Clin Invest 2000;105:401-407.
40. Akhtar M, Cheng Y, Magno RM. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001;61:2399-2403.
41. Ahluwalia A, Yan P, Hurteau JA. DNA methylation and ovarian cancer I: Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001;82:261-268.
42. Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP. DNA methylation in ovarian cancer. II: Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 2001;82:299-304.
43. Barbieri R, Mischiati C, Piva R. DNA methylation of the Haras-1 oncogene in neoplastic cells. Anticancer Res 1989;9:1787-1791.
44. Kanada M, Delia D, Aiello A. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-1828.
45. Ray JS, Harbison ML, McClain RM, Goodman JI. Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse live tumours. Mol Carcinog 1994;9:155-166.
46. Stephenson J, Akdag R, Ozbek N, Mufti GJ. Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukemia. Leuk Res 1993;17:291-293.
47. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107.
48. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, Van Engeland M, Weijenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulatedby demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-149.
49. Yamashita K, Upadhyay S, Osada M, Hoque OM, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-495.
50. Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH, Baylin SB. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;63:7089-7093.
51. Momparler RL, Cote S, Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-aza-2′-deoxycytidine (decitabine) for the therapy of leukemia. Leukemia 1997;11:1-6.
52. Wu J, Grunstein M. 25 years after the nucleosome model: Chromatin modifications. Trends Biochem Sci 2000;25:612-623.
53. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997;389:251-260.
54. Jendwein T, AlHs CD. Translating the histone code. Science 2001;293:1074-1080.
55. Turner BM. Histone acetylation and an epigenetic code. BioEssay 2000;22:836-845.
56. Van Holde KE. Chromatin. New York: Springer; 1998. pp 111-148.
57. Wolffe AP, Hayes JJ. Chromatin disruption and modification. Nucleic Acid Res 1999;27:711-720.
58. Hecht A, Laroche T, Strahl-Bolsinger S, Gasser SM, Grunstein M. Histone H3 and H4 N-termini interact with SIR3 and SIR4 proteins: A molecular model for the formation of heterochromatin in yeast. Cell 1995;80:583-592.
59. Edmonson DG, Smith MM, Roth SY. Repression domain of the yeast global represser Tup1 interacts directly with histones H3 and H4. Genes Dev 1996;10:1247-1259.
60. Bird A. Methylation talk between histones and DNA. Science 2001;294:2113-2115.
61. Bannister AJ, Zegerman P, Partridge JF. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001;410:120-124.
62. Nakayama JI, Rice JC, Strahl BD. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001;292:110-113.
63. Kouzarides T. Acetylation: A regulatory modification to rival phosphorylation? EMBO J 2000;19:1176-1179.
64. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-352.
65. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998;12:599-606.
66. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9: 40-48.
67. Davie JR. Covalent modifications of histones expression from chromatin templates. Curr Opin Genet Dev 1998;8:173-178.
68. Davie JR, Spencer VA. Control of histone modifications. J Cell Biochem 1999;Suppl:141-148.
69. Turner BM. Histone acetylation and epigenetic code. Bioessays 2000;22:836-845.
70. Turner BM, Birley AJ, Lavender J. Histone H4 isoforms acetylated at specific lysine residues define individual chromosomes and chromatin domains in Drosophila polytene nuclei. Cell 1992;69:375-384.
71. De Rubertis F, Kadosh D, Henchoz S, Pauli D, Reuter G, Struhl K, Spierer P. The histone deacetylase Rpd3 counteracts genomic silencing in Drosophila and yeast. Nature 1996;384:589-591.
72. Allfrey VG. Structural modifications of histones and their possible role in the regulation of ribonucleic acid synthesis. Proc Can Cancer Conf 1966;6:313-335.
73. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20:615-626.
74. Bannister AJ, Miska EA. Regulation of gene expression by transcription factor acetylation. Cell Mol Life Sci 2000;57:1184-1192.
75. Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY, Allis CD. Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996;84:843-851.
76. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-959.
77. Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, Owen-Hughes T, Workman J, Wang L, Berger SL, Kouzarides T, Nakatani Y, Allis CD. The TAF(II)250 subunit of TF(II)D has histone acetyltransferase activity. Cell 1996;87:1261-1270.
78. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Steroid receptor coactivator-1 is a histone acetyltransferases. Nature 1997;389:194-198.
79. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120.
80. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001;1:194-202.
81. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262:75-83.
82. Alland L, Muhle R, Hou JR. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997;387:49-55.
83. Heinzel T, Lavinsky RM, Mullen TM. A complex containing N-CoR, mSin3, and histone deacetylase mediates transcriptional repression. Nature 1997;387:43-48.
84. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001;11:162-166.
85. Umov FD, Wolffe A. Chromatin organization and human disease. Emerg Ther Targets 2000;4:665-685.
86. Cress WD, Seto E. Histone deacetylases, transcriptional control and cancer. J Cell Physiol 2000;184:1-16.
87. Grozinger CM, Schreiber SL. Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. Chem Biol 2002;9:3-16.
88. Burke LJ, Baniahmad A. Co-repressors 2000. FASEB J 2000;14:1876-1888.
89. Wade PA. Transcriptional control at regulatory check-points by histone deacetylases: Molecular connections between cancer and chromatin. Hum Mol Genet 2001;10:693-698.
90. Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA 2000;97:7825-7840.
91. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, Wu CW. Histone deacetylases specifically down-regulation p53-dependent gene activation. J Biol Chem 2000;275:20436-20443.
92. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumour activity against breast cancer in vivo. Clin Cancer Res 2001;7:971-976.
93. Chan HM, Kastic-Demonacos M, Smith L. Acetylation control of the retinoblastoma tumour-suppressor protein. Mol Cell Biol 2001;3:667-674.
94. Jacobson S, Pillus L. Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 1999;9:175-184.
95. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9: 40-48.
96. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
97. Mahiknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000;6:623-644.
98. Moller C, Leutz A. Chromatin remodelling in development and differentiation. Curr Opin Genet Dev 2001;11:167-174.
99. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1-β induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-6903.
100. 2/M checkpoint Rad proteins. J Biol Chem 2000;275:27909-27916.
101. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1, and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000;25:338-342.
102. Smirnov DA, Hou S, Ricciardi RP. Association of histone deacetylase with COUP-TF in tumorigenic Ad 12-transformed cells and its potential role in shut-off of MHC class I transcription. Virology 2000; 268:319-328.
103. Giles RH, Peters DJ, Breuning MH. Conjuction dysfunction: CBP/p300 in human disease. Trends Genet 1998;14:178-183.
104. Gayther SA, Batley SJ, Linger L, Bannister A. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000;24:300-303.
105. Murata T, Kurokawa R, Krones A. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum Mol Genet 2001;10:1071-1076.
106. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000; 14:1553-1577.
107. Magnaghi-Jaulin L, Groisman R, Naguibneva I. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998;391:601-605.
108. Murphy M, Ahn J, Walker KK. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999;13:2490-2501.
109. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 1999;96:4983-4988.
110. Fenick R, Hiebert SW. Role of histone deacetylase in acute leukemia. J Cell Biochem 1998;31: 194-202.
111. He L-Z, Tolentino T, Grayson P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:321-1330.
112. Lin RJ, Stemsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001;20:7204-7215.
113. Zelent A, Guidez F, Melnick A, Waxman S, Licht JD. Translocations of the RARa gene in acute promyelocytic leukemia. Oncogene 2001;20:7186-7203.
114. Pandolfi PP. Transcription therapy for cancer. Oncogene 2001;20:3116-3127.
115. Marks PA, Rifkind RA. Erythroleukemic differentiation. Ann Rev Biochem 1978;47:419-478.
116. Marks PA, Rifkind RA, Richon VM. Deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer I 2000;92:1210-1216.
117. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 2001;12:294-300.
118. Marks PA, Richon VM, Breslow R. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13:477-485.
119. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002;13:1-13.
120. Butler LM, Agus D, Scher HI. Suberoylanilide hydroxamic acid: An inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-5170.
121. Butler LM, Webb Y, Agus DB. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide: An inhibitor of histone deacetylase. Clin Cancer Res 2001;7:962-970.
122. Qui L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parson PG. Antitumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999;80:1252-1258.
123. Parson PG, Hansen C, Fairlie DP. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem Pharmacol 1997;53:1719-1724.
124. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Expr 1996;5:245-254.
125. Suzuki H, Gabrielson E, Chen W. A genomic screen for genes upregulated by and histone deacetylase inhibitors in human colorectal cancer. Nat Genet 2002;31:141-149.
126. Marladason JM, Corner GA, Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: Comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 2000;60:4561-4572.
127. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000;6:849-866.
128. Xiao H, Horinouchi S, Beppu T. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999;73:291-302.
129. Zhang Y, Reinberg D. Transcription regulation by histone methylation: Interplay between different covalent modifications of the core histone tails. Genes Dev 2001;15:2343-2360.
130. Richon VM, Sandhoff TW, Rifkind RA. Histone deacetylase inhibitors selectively induce p21waf1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-10019.
131. Butler LM, Zhou X, Xu WS. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and regulates thioredoxin. Proc Natl Acad Sci USA 2002; 99:11700-11705.
132. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98:10833-10838.
133. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003;2: 30-37.
134. Kwon SH, Ahn SH, Kim YK, Bae G-U, Yoon JW, Hong S, Lee HY, Lee Y-W, Lee H-W, Han J-W. Apicidin: A histone deacetylase inhibitor, induces apoptosis and FAS/FAS ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002;277:2073-2080.
135. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 2004;259:249-266.
136. Magner WJ. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 2000;165:7017-7024.
137. Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD 154, interleukin 10, and interferon-γ gene and protein expression in lupus T cells. Proc Natl Acad Sci USA 2001;98:2628-2633.
138. Maeda T, Towatani M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000;96:3847-3856.
139. Kim MS. Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes. Nat Med 2001;7:437-443.
140. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002;97:290-296.
141. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V. HDAC inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21:427-436.
142. Longhurst HJ, Holder AA. The histones of Plasmodium falciparum: Identification, purification, and a possible role in the pathology of malaria. Parasitology 1997;114:413-419.
143. Darkin-Rattray SJ, Gurnett AM, Myers RW. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci USA 1996;93:13143-13147.
144. Belli SI. Chromatin remodelling during life cycle of trypanosomatids. Int J Parasitol 2000;30:679-687.
145. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Lee YW, Lee HW. Apicidin: A histone deacetylase inhibitor, inhibits proliferation of tumour cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Research 2000;60:6068-6074.
146. Andrews KT, Walduck A, Kelso MJ, Fairlie DP, Saul A, Parsons PG. Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int J Parasitol 2000;30:761-768.
147. Mai A, Massa S, Cerbara I, Valente S, Walker LA, Tekwani BL. Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides: A new class of histone deacetylase inhibitors. Antimicrob Agents Chemother 2004;48:1435-1436.
148. Impagnatiello F, Guidotti AR, Pesold C. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998;95:15718-15723.
149. Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology. Neuron 2000;28:325-334.
150. Costa E, Chen Y, Davis J, Dong E, Noh JS, Tremolizzo L, Veldic M, Grayson DR, Guidotti A. Reelin and schizophrenia: A disease at the interface of genome and epigenome. Mol Interv 2002;2:47-57.
151. Hakimi MA, Dong Y, Lane WS, Speicher DW, Shiekhattar R. A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes. J Biol Chem 2003;278:7234-7239.
152. Steffan JS, Bodai L, Palios J, Kazantsev A, Schmidt E, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413:739-743.
153. Wagner M, Brosch G, Zwerschke W, Seto E, Loidl P, Jansen P. Histone deacetylase in replicative senescence: Evidence for a senescence-specific form of HDAC-2. FEBS Lett 2001;499:101-106.
154. Chang KT, Min K-T. Regulation of lifespan by histone deacetylase. Ageing Res Rev 2002;1:313-326.
155. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide: A putative negative regulator of yeast Sir2 and human SIRT1. J Biol Chem 2002;277:45099-45107.
156. Kao H-Y, Lee C-H, Komarov A. Isolation and characterization of mammalian HDAC10: A novel histone deacetylase. J Biol Chem 2002;277:187-193.
157. Gao L, Cueto MA, Asselbergs F, Ataoja P. Clonino and functional characterization of HDAC11: A novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-25755.
158. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 1999;96:4868-4873.
159. Bertos NR, Wang AH, Yang XY. Class II histone deacetylases: Structure, function, and regulation. Biochem Cell Biol 2001;79:243-252.
160. Yang XY, Seto E. Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev 2003;13:143-153.
161. Fischle W, Kiermer V, Dequiedt F, Verdin E. The emerging role of class II histone deacetylases. Biochem Cell Biol 2001;79:337-348.
162. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylase act as signal-responsive repressers of cardiac hypertrophy. Cell 2002;110:479-488.
163. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Quin J, Wong J. Purification and functional characterization of the human N-CoR complex: The roles of HDAC3, TBL1, and TBLR1. EMBO J 2003;22:1336-1346.
164. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000;273:793-798.
165. Chang JH, Kim HC, Hwang KY, Lee JW, Jackson SP, Bell SD, Cho Y. Structural basis for the NAD-dependent deacetylase mechanism of Sir 2. J Biol Chem 2002;277:34489-34498.
166. Luo G. Negative control of p53 by Sir2α promoters cell survival under stress. Cell 2001;107:137-148.
167. Vaziri H. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159.
168. Afshar G, Murnane JP. Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2. Gene 1999;234:161-168.
169. Finnin MS, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193.
170. +-dependent deacetylases. J Biol Chem 2002;277:12632-12641.
171. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179.
172. Kijima M, Yoshida M, Suguta K, Horinouchi S, Beppu T. Trapoxin: An antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 1993;268:22429-22435.
173. Glosse A, Hugenin R. Isolation and structure elucidation of chlamydocin. Helv Chim Acta 1974;57: 533-545.
174. Shute RE, Dunlap B, Rich DH. Analogues of the cytostatic and antimitogenic agents chlamydocin and HC-toxin: Synthesis and biological activity of chloromethyl ketone and diazomethyl ketone functionalized cyclic tetrapeptides. J Med Chem 1987;30:71-78.
175. Hirota A, Suzuki A, Aizawa K, Tamura S. Mass spectrometric determination of amino acid sequence in Cyl-2: A novel cyclotetrapeptide from Cylindrocladium scoparium. Biomed Mass Spectrom 1974; 1:15-19.
176. Umehara K, Nakahara K, Kiyoto S, Iwami M, Okamoto M, Tanaka H, Kohsaka M, Aoki H, Imanaka H. Studies on WF-3161: A new antitumor antibiotic. J Antibiot 1983;36:478-483.
177. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M. FR901228: A novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical, and biological properties, and antitumor activity. J Antibiot 1994;47:301-310.
178. Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 1998;95:3356-3361.
179. Kruh J. Effects of sodium butyrate: A new pharmacological agent, on cells in culture. Mol Cell Biochem 1982;42:65-82.
180. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998; 95:3003-3007.
181. Jung M, Brosch G, Kölle D, Scherf H, Gerhäuser C, Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem 1999;42:4669-4679.
182. Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, Howell KL, Jung M, Known P, Trogani N, Walker H. Inhibitors of human histone deacetylase: Synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem 2002;45:753-757.
183. Woo SH, Frechette S, Khalil EA, Bouchain G, Vaisburg A, Bernstein N, Moradei O, Leit S, Allan M, Fournel M, Trachy-Bourget MC, Li Z, Besterman JM, Delorme D. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J Med Chem 2002;45:2877-2885.
184. Uesato S, Kitagawa M, Nagaoka Y, Maeda T, Kuwajima H, Yamori T. Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorg Med Chem Lett 2002;12:1347-1349.
185. Su GH, Sohn TA, Ryu B, Kern SE. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 2000;60:3137-3142.
186. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 1999;18:2461-2470.
187. Lavoie R, Bouchain G, Frechette S, Woo SH, Khalil EA, Leit S, Fournel M, Yan PT, Trachy-Bourget MC, Beaulieu C, Li Z, Besterman JM, Delorme D. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett 2001;11:2847-2850.
188. Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc Natl Acad Sci USA 2001;98:87-92.
189. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace R, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumour activity: Discovery of (2E)-/V-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 2003;46:4609-4624.
190. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-275, with marked in vivo antitumour activity against human tumors. Proc Natl Acad Sci USA 1999;96:4592-4597.
191. Frey RR, Wada CK, Garland RB, Davidsen SK. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2002;12:3443-3447.
192. Vasudevan A, Ji Z, Frey RR, Wada CK, Steinman D, Heyman HR, Guo Y, Curtin ML, Guo J, Li J, Pease L, Glaser KB, Marcotte PA, Bouska JJ, Davidsen SK, Michaelides MR. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2003;13:3909-3913.
193. Carducci MA, Bowling MK, Eisenberger M. Phenylbutyrate (PB) for refractory solid tumours: Phase I clinical and pharmacologic evaluation of intravenous and oral PB. Anticancer Res 1997;17:3972-3973.
194. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
195. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot 1976;29:1-6.
196. Tsuji N, Kobayashi M. Trichostatin C: A glucopyranosyl hydroxamate. J Antibiot 1978;31:939-944.
197. Yoshida M, Nomura S, Beppu T. Effects of trichostatins on differentiation of murine erythroleukemia cells. Cancer Res 1987;47:3688-3691.
198. Yoshida M, Horinouchi S, Beppu T. Trichostatin and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 1995;17:423-430.
199. Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin: A specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J Antibiot 1990;43:1101-1106.
200. 2 phases by trichostatin A. Exp Cell Res 1988;177:122-131.
201. Itazaki H, Nagashima K, Sugita K, Yoshida M, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumour agents. J Antibiot 1990;43:1524-1532.
202. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272:408-411.
203. Vigushin DM. FR-901228 Fujisawa/National Cancer Institute. Curr Opin Investig Drugs 2002;3:1396-1402.
204. Shimada J, Kwon HJ, Sawamura M, Schreiber SL. Synthesis and cellular characterization of the detransformation agent, (-)-depudecin. Chem Biol 1995;2:517-525.
205. Breslow R, Jursic B, Yan ZF, Friedman E, Leng L, Ngo L, Rifkind RA, Marks PA. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci USA 1991;88:5542-5546.
206. Prakash S, Foster B, Meyer M. Chronic administration of CI-994: A phase I study. Invest New Drugs 2001;19:1-11.
207. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998;90:1621-1625.
208. Zhou D, Kim S, Ding W, Schultz C, Warrell R, Gallagher R. Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and deacetylase inhibitors in vitro and in vivo. Blood 2002;99:1356-1363.
209. Novich S. Initial clinical evaluation of 'transcription therapy' for cancer: All-trans retinoic acid plus phenylbutyrate. Blood 1999;94:61A.
210. Grozinger MC, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001;276:38837-38843.
211. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001;98:15113-15118.
212. Massa S, Artico M, Corelli F, Mai A, Di Santo R, Cortes S, Marongiu ME, Pani A, La Colla P. Synthesis and antimicrobial and cytotoxic activities of pyrrole-containing analogues of trichostatin A. J Med Chem 1990;33:2845-2849.
213. Corelli F, Massa S, Stefancich G, Mai A, Artico M, Panico S, Simonetti N. Ricerche su composti antibatterici ed antifungini. Nota VIII - Sintesi ed attività antifungina di derivati pirrolici correlati con la tricostatina A. (Researches on antibacterial and antifungal agents. VIII. Synthesis and antifungal activity of trichostatin A-related pyrrole derivatives.) Farmaco Ed Sci 1987;42:893-903.
214. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi T. The protein data bank: A computer based archival file for macromolecular structures. J Mol Biol 1977;112:535-542.
215. Mohamadi F, Richards NGJ, Guida WC, Liskamp R, Lipton M, Caufield C, Chang G, Hendrickson T, Still WC. MACROMODEL - An integrated software system for modelling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990;11:440-467.
216. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, Debolt S, Ferguson DM, Seibel GL, Kollman PA. AMBER: A package of computer programs for applying molecular mechanics, normal-mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 1995;9:1-41.
217. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, Ferguson DM, Seibel G, Singh UC, Weiner PK, Kollman PA. AMBER 4.1. San Francisco, CA: Department of Pharmaceutical Chemistry, University of California 1995.
218. Head RD, Smythe ML, Oprea TI, Waller CL, Green SM, Marshall GR. VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands. J Am Chem Soc 1996;118:3959-3969.
219. Manuscript in preparation. Briefly: The original VALIDATE procedure was modified applying semiempirical AM1 calculated charges (keyword MOZYME in MOPAC 200068) to the training set and prediction set complexes. The use of such atomic charges improved the predictability of the VALIDATE method towards those complexes in which are involved proteins or enzymes containing metal cations as in the case of HDLP.
220. Stewart JJP. MOPAC 2000.00 Manual. Tokyo, Japan: Fujitsu Limited, 1999.
221. This VALIDATE model has been obtained using 86 ligand/protein complexes including the HDLP/TSA complex.
222. Massa S, Mai A, Sbardella G, Esposito M, Ragno R, Loidl P, Brosch G. 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides: A new class of synthetic histone deacetylase inhibitors. J Med Chem 2001; 44:2069-2072.
223. Lechner T, Lusser A, Brosch G, Eberharter A, Goralik-Schramel M, Loidl P. A comparative study of histone deacetylases of plant, fungal, and vertebrate cells. Biochim Biophys Acta 1996;1296:181-188.
224. Lusser A, Brosch G, Loidl A, Haas H, Loidl P. Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein. Science 1997;277:88-91.
225. Weidle UH, Grossmann A. Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 2000;20:1471-1486.
226. Brosch G, Lusser A, Goralik-Scramel M, Loidl P. Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. Biochemistry 1996;35:15907-15914.
227. Kolle D, Brosch G, Lechner T, Lusser A, Loidl P. Biochemical methods for analysis of histone deacetylases. Methods 1998;15:323-331.
228. Kolle D, Brosch G, Lechner T, Pipal A, Helliger W, Taplick J, Loidl P. Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry 1999; 38:6769-6773.
229. Brosch G, Ransom R, Lechner T, Walton J, Loidl P. Inhibition of maize histone deacetylases by HC toxin: The host-selective toxin of Cochliobolus carbonum. Plant Cell 1995;33:1941-1950.
230. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22: 3099-3108.
231. Khochbin S, Wolffe AP. The origin and utility of histone deacetylases. FEBS Lett 1997;419:157-160.
232. Sendra R, Rodrigo I, Salvador ML, Franco L. In vitro anti-HDAC1 activity was determined by us as described in characterization of pea histone deacetylases. Plant Mol Biol 1988;11:857-866.
233. Mai A, Massa S, Ragno R, Esposito M, Sbardella G, Nocca G, Scatena R, Jesacher F, Loidl P, Brosch G. Binding mode analysis of 3-(4-benzoyl-1-methyl- 1H-2-pyrrolyl)-N-hydroxy-2-propenamide: A new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation. J Med Chem 2002;45:1778-1784.
234. Mai A, Massa S, Ragno R, Cerbara I, Jesacher F, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. J Med Chem 2003;46:512-524.
235. Oshiro CM, Kuntz ID, Dixon JS. Flexible ligand docking using a genetic algorithm. J Comput Aided Mol Des 1995;9:113-130.
236. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: Applications of AutoDock. J Mol Recognit 1996;9:1-5.
237. Mai A, Massa S, Cerbara I, Valente S, Ragno R, Bottoni P, Scatena R, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole C2 and/or C4 substitutions on biological activity. J Med Chem 2004; 47:1098-1109.
238. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46:5097-5116.
239. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediate tubulin deacetylation. Proc Natl Acad Sci USA 2003; 100:4389-4394.
240. Mai A, Massa S, Pezzi R, Rotili D, Loidl P, Brosch G. Discovery of (aryl-oxopropenyl) pyrrolyl-hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J Med Chem 2003;46:4826-4829.
241. Ragno R, Mai A, Massa S, Cerbara I, Valante S, Bottoni P, Scatena R, Jesacher F, Loidl P, Brosch G. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2- propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J Med Chem 2004;47:1351-1359.